We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Cardiac Troponins Assessed for Acute Heart Failure

By LabMedica International staff writers
Posted on 17 Mar 2021
Print article
Image: The Elecsys high-sensitivity cardiac troponin T (hs-cTnT) assay: as immunological method for the in vitro quantification of cardiac troponin T in human serum and plasma (Photo courtesy of Roche Diagnostics).
Image: The Elecsys high-sensitivity cardiac troponin T (hs-cTnT) assay: as immunological method for the in vitro quantification of cardiac troponin T in human serum and plasma (Photo courtesy of Roche Diagnostics).
Heart failure (HF) is a clinical syndrome characterized by dyspnea, peripheral edema and fatigue. Diagnosing HF can be difficult due to overlapping symptoms with other conditions, and the phenotype of HF varies due to a broad spectrum of underlying pathophysiology.

Cardiac troponins are cornerstone markers for diagnosis, risk stratification and selection of treatment strategy of acute coronary syndrome (ACS). The diagnostic accuracy for ACS has greatly improved, due to novel high-sensitivity cardiac troponin (hs-cTn) assays with very low limit of detection.

A team of Medical Scientists from the Akershus University Hospital (Lørenskog, Norway) and their colleagues carried out a prospective, single-center study at the hospital conducted from June 2009 through November 2010. Of 468 patients hospitalized with acute dyspnea, 314 patients were included in the final study cohort. Blood samples were obtained within 24 hours of hospital admission in all 231 patients, and day 2 and from 95 patients before discharge, in a subgroup of the cohort. Samples were centrifuged, serum immediately frozen and stored at −80 °C before analysis. In the total population, median age was 73 years and 48% were women.

To measure cTnT concentrations, the team used the high-sensitivity assay, Elecsys TnT hs stat, (Roche Diagnostics, Penzberg, Germany). The assay has a range of detection from 3 to 10,000 ng/L, a 10% coefficient of variation of 13 ng/l, and a 99th percentile in healthy individuals of 14 ng/L. hs-cTnT values below the limit of detection were assigned the value 3 ng/L. N-terminal pro-B-type natriuretic peptide (NT-proBNP) was measured on a Cobas Platform (Roche Diagnostics, Basel, Switzerland) using the proBNP II assay, with a range of detection from 5 to 35,000 ng/L.

The team reported that 143 patients were categorized as AHF (46%) and these patients had higher hs-cTnT concentrations than patients with non-AHF-related dyspnea: median 38 (Q1-3 22–75) versus 13 (4–25) ng/L. hs-cTnT concentrations were similar between patients with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), in contrast to NT-proBNP, which was higher in HFrEF. During median 27 months of follow-up, 114 (36%) patients died in the total population. Higher hs-cTnT concentrations were associated with increased risk of all-cause mortality after adjustment for clinical variables and NT-proBNP: hazard ratio 1.30 (95% CI 1.07–1.58).

The authors concluded that hs-cTnT provides useful diagnostic information among patients admitted to the Emergency Department with dyspnea. In particular, elevated hs-cTnT seems to be valuable in identifying patients with HFpEF. The hs-cTnT also provides prognostic information for an unselected population with dyspnea, but a larger cohort is needed to examine the prognostic value of hs-cTnT for the subgroup of HF/HFrEF/HFpEF patients. The study was published in the February 2021 issue of the journal Clinical Biochemistry.

Related Links:
Akershus University Hospital
Roche Diagnostics Germany
Roche Diagnostics


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays
New
Coagulation Analyzer
CS-2400

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.